Correction to: Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
1 Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI‑MAG) of the Helmholtz Zentrum München, University of Leipzig and University Hospital Leipzig, Leipzig, Germany. matthias.blueher@medizin.uni-leipzig.de.
2 Velocity Clinical Research, Medical City, Dallas, TX, USA.
3 Staburo GmbH, Munich, Germany, on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
4 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
5 Boehringer Ingelheim International GmbH, Biberach an der Riß, Germany. anita.hennige@boehringer-ingelheim.com.